

## Cambia<sup>®</sup> (diclofenac potassium) – First-time authorized brand alternative

- On January 3, 2023, Leading Pharma launched an authorized brand alternative of Assertio Therapeutics' <u>Cambia (diclofenac potassium)</u> oral solution.
  - Par, Annora and Alkem received FDA approval of AB-rated generic versions of Cambia on May 2, 2016, March 4, 2022, and July 20, 2022, respectively. Launch plans for these generics are pending.
- Cambia is approved for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older).
- Cambia carries a boxed warning for risk of serious cardiovascular and gastrointestinal events.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.